E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.

@article{Gorgun2009EmuTCL1MR,
  title={E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.},
  author={Gullu Gorgun and Alan G Ramsay and Tobias A. W. Holderried and David Zahrieh and Rifca Le Dieu and Fenglong Liu and John Quackenbush and Carlo Maria Croce and John G Gribben},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2009},
  volume={106 15},
  pages={
          6250-5
        }
}
Preclinical animal models have largely ignored the immune-suppressive mechanisms that are important in human cancers. The identification and use of such models should allow better predictions of successful human responses to immunotherapy. As a model for changes induced in nonmalignant cells by cancer, we examined T-cell function in the chronic lymphocytic leukemia (CLL) Emu-TCL1 transgenic mouse model. With development of leukemia, Emu-TCL1 transgenic mice developed functional T-cell defects… CONTINUE READING

Figures and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 67 CITATIONS, ESTIMATED 58% COVERAGE

FILTER CITATIONS BY YEAR

2009
2018

CITATION STATISTICS

  • 2 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

AG Ramsay
  • J Clin Invest
  • 2008
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells

G Gorgun
  • J Clin Invest
  • 2005
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia

AJ Johnson
  • 2006
VIEW 1 EXCERPT

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

A Chanan-Khan
  • J Clin Oncol
  • 2006
VIEW 1 EXCERPT